183 related articles for article (PubMed ID: 23959266)
1. ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity.
Ait-Tihyaty M; Rachid Z; Larroque-Lombard AL; Jean-Claude BJ
Invest New Drugs; 2013 Dec; 31(6):1409-23. PubMed ID: 23959266
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda.
Ait-Tihyaty M; Rachid Z; Mihalcioiu C; Jean-Claude BJ
Breast Cancer Res Treat; 2012 May; 133(1):217-26. PubMed ID: 21915635
[TBL] [Abstract][Full Text] [Related]
3. Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5'-deoxy-5-fluorocytidine formation.
Tabata T; Katoh M; Tokudome S; Hosakawa M; Chiba K; Nakajima M; Yokoi T
Drug Metab Dispos; 2004 Jul; 32(7):762-7. PubMed ID: 15205393
[TBL] [Abstract][Full Text] [Related]
4. Comparison of in vitro metabolic conversion of capecitabine to 5-FU in rats, mice, monkeys and humans--toxicological implications.
Shindoh H; Nakano K; Yoshida T; Ishigai M
J Toxicol Sci; 2011 Aug; 36(4):411-22. PubMed ID: 21804305
[TBL] [Abstract][Full Text] [Related]
5. [Discovery and development of novel anticancer drug capecitabine].
Ishitsuka H; Shimma N; Horii I
Yakugaku Zasshi; 1999 Dec; 119(12):881-97. PubMed ID: 10630095
[TBL] [Abstract][Full Text] [Related]
6. The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine.
Shimma N; Umeda I; Arasaki M; Murasaki C; Masubuchi K; Kohchi Y; Miwa M; Ura M; Sawada N; Tahara H; Kuruma I; Horii I; Ishitsuka H
Bioorg Med Chem; 2000 Jul; 8(7):1697-706. PubMed ID: 10976516
[TBL] [Abstract][Full Text] [Related]
7. Rational design of new tumoractivated cytotoxic agents.
Verweij J
Oncology; 1999 Jul; 57 Suppl 1():9-15. PubMed ID: 10436411
[TBL] [Abstract][Full Text] [Related]
8. Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase.
Di Gennaro E; Piro G; Chianese MI; Franco R; Di Cintio A; Moccia T; Luciano A; de Ruggiero I; Bruzzese F; Avallone A; Arra C; Budillon A
Br J Cancer; 2010 Nov; 103(11):1680-91. PubMed ID: 21045833
[TBL] [Abstract][Full Text] [Related]
9. Development of a UPLC-MS/MS Assay for the Quantitative Determination of Capecitabine, 5'-deoxy-5-fluorocytidine (5'-dFCR), 5'-deoxy-5-fluorouridine (5'-dFUR), 5'-fluorouracil (5-FU), and α-fluoro-β-alanine (FBAL).
Knikman JE; de Vries N; Rosing H; Cats A; Guchelaar HJ; Beijnen JH
Pharmazie; 2023 Aug; 78(8):107-112. PubMed ID: 37592424
[TBL] [Abstract][Full Text] [Related]
10. Interferon-α enhances 5'-deoxy-5-fluorouridine-induced apoptosis by ERK-dependant upregulation of thymidine phosphorylase.
Zhu Y; Xu L; Fan Y; Li C; Zhang Y; Zheng H; Hou K; Qu X; Liu Y
Biomed Res Int; 2013; 2013():132793. PubMed ID: 24027750
[TBL] [Abstract][Full Text] [Related]
11. ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine.
Magné N; Fischel JL; Dubreuil A; Formento P; Ciccolini J; Formento JL; Tiffon C; Renée N; Marchetti S; Etienne MC; Milano G
Clin Cancer Res; 2003 Oct; 9(13):4735-42. PubMed ID: 14581344
[TBL] [Abstract][Full Text] [Related]
12. Hydrolysis of capecitabine to 5'-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide.
Quinney SK; Sanghani SP; Davis WI; Hurley TD; Sun Z; Murry DJ; Bosron WF
J Pharmacol Exp Ther; 2005 Jun; 313(3):1011-6. PubMed ID: 15687373
[TBL] [Abstract][Full Text] [Related]
13. Preferential inhibition of bone metastases by 5'-deoxy-5-fluorouridine and capecitabine in the 4T1/luc mouse breast cancer model.
Hiraga T; Hata K; Ikeda F; Kitagaki J; Fujimoto-Ouchi K; Tanaka Y; Yoneda T
Oncol Rep; 2005 Sep; 14(3):695-9. PubMed ID: 16077977
[TBL] [Abstract][Full Text] [Related]
14. Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes.
Yasuno H; Kurasawa M; Yanagisawa M; Sato Y; Harada N; Mori K
Oncol Rep; 2013 Feb; 29(2):451-8. PubMed ID: 23229803
[TBL] [Abstract][Full Text] [Related]
15. Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.
Takechi T; Okabe H; Ikeda K; Fujioka A; Nakagawa F; Ohshimo H; Kitazato K; Fukushima M
Oncol Rep; 2005 Jul; 14(1):33-9. PubMed ID: 15944764
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacological and clinical properties of Xeloda (Capecitabine), a new oral active derivative of fluoropyrimidine].
Nishida M
Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):549-53. PubMed ID: 14639009
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry.
Deng P; Ji C; Dai X; Zhong D; Ding L; Chen X
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 May; 989():71-9. PubMed ID: 25808944
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts.
Kataoka M; Yamaguchi Y; Moriya Y; Sawada N; Yasuno H; Kondoh K; Evans DB; Mori K; Hayashi S
Oncol Rep; 2012 Feb; 27(2):303-10. PubMed ID: 22076074
[TBL] [Abstract][Full Text] [Related]
19. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
Miwa M; Ura M; Nishida M; Sawada N; Ishikawa T; Mori K; Shimma N; Umeda I; Ishitsuka H
Eur J Cancer; 1998 Jul; 34(8):1274-81. PubMed ID: 9849491
[TBL] [Abstract][Full Text] [Related]
20. [Mechanism and possible biochemical modulation of capecitabine (Xeloda), a newly generated oral fluoropyrimidine].
Saeki T; Takashima S
Gan To Kagaku Ryoho; 1999 Mar; 26(4):447-55. PubMed ID: 10097741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
